Brookline Capital Markets Reiterates Buy Rating on Intellia Therapeutics (NTLA)

Intellia Therapeutics (NTLA) Announces Positive Clinical Proof-of-Concept Data for Redosing a CRISPR-Based Therapy with its Proprietary LNP-Based Delivery Platform

Intellia Therapeutics, Inc. (NASDAQ: NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based therapies, today presented new data demonstrating for the first time the potential for redosing with an investigational, in vivo CRISPR/Cas9 genome editing therapy. These data from the ongoing Phase 1 study of NTLA-2001, a single-dose treatment in development for transthyretin (ATTR) amyloidosis, were presented at the Peripheral Nerve Society Annual Meeting, taking place June 2225 in Montreal, Canada.

Todays data showcase an exciting new platform advancement for Intellia and the field of gene editing.... More

Stifel on Intellia Therapeutics (NTLA): 'Positive Ph.3 HELIOS-B data this morning validates the NTLA-2001 approach'

Stifel analyst Dae Gon Ha reiterated a Buy rating and $80.00 price target on Intellia Therapeutics (NASDAQ: NTLA).

The analyst comments "Positive Ph.3 HELIOS-B data this morning validates the NTLA-2001 approach and with the Ph.3 MAGNITUDE study ongoing, should be seen... More

Truist Securities Reiterates Buy Rating on Intellia Therapeutics (NTLA)

Truist Securities analyst Joon Lee reiterated a Buy rating and $120.00 price target on Intellia Therapeutics (NASDAQ: NTLA).

The analyst comments "This morning, Alnylam (ALNY, NR) shared topline data from the highly anticipated HELIOS-B study of Vutrisiran (25mg, quarterly dosing for 36 months) in ATTR-CM (NCT04153149). The results represent best-case scenario for ALNY, hitting on all primary and secondary endpoints (Exhibit 1). This is also a positive for NTLA's NTLA-2001 for the same indication of ATTR given '2001's similarly deep TTR reduction without the peaks and troughs of repeat siRNA injections, In... More

Baird on Intellia Therapeutics (NTLA): 'we anticipate enthusiasm will wane'

Baird analyst Jack Allen reiterated a Neutral rating and $24.00 price target on Intellia Therapeutics (NASDAQ: NTLA).

The analyst comments "No change to outlook on competitor's clinical data. This morning, Alnylam (ALNY, not covered) announced positive top-line results from the HELIOS-B study of their... More

Alnylam (ALNY) data is positive for Ionis (IONS), Intellia (NTLA) and negative for BridgeBio (BBIO) - analyst

Alnylam Pharma (NASDAQ: ALNY) data is positive for Ionis Pharmaceuticals (NASDAQ: IONS) and Intellia Therapeutics (NASDAQ: NTLA) and negative for BridgeBio Pharma Inc. (NASDAQ: BBIO), according to analysts at BMO.... More